Federal authorities on Thursday announced initial funding to examine the clinical potential of ibogaine, a controversial psychedelic compound supported by veterans, conservative lawmakers, and podcasters allied with President Donald Trump .
Health Secretary Robert F. Kennedy Jr. confirmed the department will provide up to $4.9 million to prepare for the first U.S. trials evaluating ibogaine for post-traumatic stress disorder, a difficult condition tied to elevated suicide and substance abuse among veterans.
The grant will not fund direct patient research, Kennedy noted, but will establish the foundation required to produce, dose, and design clinical evaluations of the compound.
Derived from a West African shrub, ibogaine can cause intense hallucinations, nausea, vomiting, tremors, and severe heart rhythm issues.
It remains illegal under federal law, categorized in the same restrictive classification as LSD, ecstasy , and most other hallucinogens.
Veterans groups and advocates for psychedelics argue that…